Announcements
- argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
- argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
- argenx Appoints Ana Cespedes to Board of Directors
- argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- argenx to Present at Upcoming Investor Conferences
- argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
More ▼
Key statistics
Markit short selling activity
Open | 63.90 |
---|---|
High | 63.90 |
Low | 63.90 |
Bid | -- |
Offer | -- |
Previous close | 63.90 |
Average volume | -- |
---|---|
Shares outstanding | 55.47m |
Free float | 55.47m |
P/E (TTM) | -- |
Market cap | 19.57bn EUR |
EPS (TTM) | -16.28 EUR |
Data delayed at least 15 minutes, as of Oct 12 2018.
More ▼